Skin & Subcutaneous Tissue

Urticaria and angioedema: chronic management

Clinical Overview and When to Suspect Chronic Urticaria/Angioedema

— Chronic urticaria (CU): recurrent wheals, angioedema, or both lasting ≥6 weeks

— Chronic spontaneous urticaria (CSU): no identifiable external trigger (~two-thirds of cases)

— Chronic inducible urticaria (CIndU): reproducible trigger (cold, pressure, cholinergic, dermographism, solar, aquagenic, vibratory)

— Lifetime prevalence ~20% for any urticaria; CU ~1% of US adults

— Female predominance ~2:1; peak age 20–40

— Median CSU duration 2–5 years; ~20% persist >5 years

— Mast cell degranulation → histamine, PAF, leukotrienes → wheal/flare and dermal/subcutaneous edema

— Autoimmune CSU: IgG autoantibodies vs FcεRI or IgE vs autoantigens (anti-TPO, anti-thyroglobulin)

— Angioedema in CSU is histaminergic (responds to antihistamines/steroids) — distinct from bradykinin-mediated HAE/ACEi angioedema

— Hives recurring most days for >6 weeks

— Patient self-medicating with OTC diphenhydramine multiple times daily

— Sleep disruption, work absenteeism, depression/anxiety screen positive

— Recurrent angioedema without wheals → think bradykinin pathway (HAE, ACEi)

— Urticaria Control Test (UCT) and UAS7 are validated, free, and should be tracked at every visit

— DLQI scores in CSU rival those of psoriasis and ischemic heart disease

Definition

Epidemiology

Pathophysiology snapshot

When to suspect chronic disease (outpatient red flags)

Step 3 management: In family medicine, the most common pitfall is over-ordering allergy panels. CSU is a clinical diagnosis; extensive food/inhalant IgE testing is not recommended unless history points to a specific reproducible trigger. Order only CBC, CRP/ESR, and TSH as routine screening.

Quality-of-life impact

Board pearl: Wheals that last >24 hours in one spot, leave bruising or hyperpigmentation, or burn rather than itch → biopsy for urticarial vasculitis, not routine CSU.

Presentation Patterns and Key History

— Pruritic, blanching, edematous pink-to-red wheals with surrounding flare

— Individual lesion lifespan <24 hours (often 1–8 hours), migratory

— No residual skin change after resolution

— Angioedema in ~40%: lips, eyelids, hands, genitals; tongue/laryngeal involvement uncommon but possible

— Duration pattern: daily vs episodic; morning vs evening predominance

— Trigger screen for CIndU:

— Cold (ice cube test history) — cold urticaria

— Tight clothing/sitting/standing for hours — delayed pressure urticaria

— Exercise/heat/emotion → small punctate wheals — cholinergic

— Scratching produces linear wheals — symptomatic dermographism

— Sun-exposed areas — solar urticaria

— NSAID, opioid, radiocontrast, alcohol exposure → pseudoallergic flare

— ACEi/ARB use → bradykinin angioedema (often no wheals)

— Recent infection (viral URI, H. pylori symptoms, parasitic exposure, dental abscess)

— Autoimmune review: thyroid sx, joint pain, sicca, photosensitivity

— Family history of angioedema without urticaria → screen for hereditary angioedema (HAE)

— UAS7: daily wheal count + pruritus intensity (0–3 each) × 7 days; max 42

— UCT (4 questions, score 0–16); ≥12 = well-controlled

— AAS (angioedema activity score) if angioedema-predominant

Classic CSU presentation

History elements that change management

Quantification at every visit

Key distinction: Recurrent angioedema without urticaria, without pruritus, with abdominal pain attacks, and not responsive to antihistamines/epinephrine → bradykinin-mediated. Stop ACEi, check C4 (low between attacks in HAE), C1-inhibitor level and function.

Step 3 management: Document medication exposures across all prescribers — ACEi started by cardiology is a frequent missed cause of recurrent angioedema in a primary care visit. Use the shared EHR med list, not patient recall.

Board pearl: A patient with "hives" leaving purpuric or hyperpigmented spots that last >24 hours and burn more than itch → urticarial vasculitis; check C3/C4, ANA, and refer for biopsy.

Physical Exam Findings and Acute Severity Assessment

— Wheals: raised, well-circumscribed, blanching, pink central edema with surrounding erythema (flare)

— Size: millimeters (cholinergic) to giant confluent plaques (CSU)

— Distribution: generalized in CSU; localized to pressure points, exposed skin, or contact areas in CIndU

— Dermographism test: stroke skin firmly with tongue blade → linear wheal within 5 min confirms symptomatic dermographism

— Non-pitting, asymmetric, non-pruritic swelling of lips, periorbital, hands, feet, genitals

— Airway assessment is mandatory at every visit with active angioedema:

— Voice change (muffled, hoarse), stridor, drooling, dysphagia, tongue protrusion

— Tripoding, accessory muscle use, oxygen saturation

— Hypotension, tachycardia, wheeze → this is anaphylaxis, not isolated urticaria → IM epinephrine 0.3–0.5 mg lateral thigh, ED transfer

— Isolated chronic urticaria without systemic features → outpatient management

— Thyroid: goiter, nodules → check TSH, anti-TPO (autoimmune thyroiditis association up to 25%)

— Joints: synovitis → consider urticarial vasculitis, SLE, Schnitzler syndrome

— Lymphadenopathy/hepatosplenomegaly → consider lymphoproliferative or mastocytosis

— Darier sign (urticarial flare on stroking a pigmented macule) → cutaneous mastocytosis

— Ask patient to photograph active lesions at home; many present after wheals have resolved

— Include a timestamped reference object to confirm <24h lesion lifespan

Skin exam

Angioedema exam

Vital signs / hemodynamic screen

Systemic exam pearls

Photographic documentation

CCS pearl: For a CCS case of "swollen lips and throat tightness" — order vitals, pulse ox, IV access, IM epinephrine, IV diphenhydramine, IV methylprednisolone, H2 blocker, continuous monitoring, and do not discharge until 4–6 h observation; prescribe epinephrine auto-injector ×2 and allergy referral on discharge.

Board pearl: Pitting edema, dependent distribution, bilateral lower extremities → that is not angioedema; reconsider heart failure, nephrotic syndrome, venous insufficiency, calcium channel blocker effect.

Diagnostic Workup — Initial Labs and Targeted Testing

— CBC with differential — eosinophilia (parasitic, drug, hypereosinophilic syndromes); basophilia/anemia (chronic disease)

— CRP and/or ESR — elevation suggests urticarial vasculitis, autoinflammatory disease, or infection rather than typical CSU

— TSH — autoimmune thyroid disease present in up to 25% of CSU

— Anti-TPO, anti-thyroglobulin if TSH abnormal or strong autoimmune family history

— C4 — screening test for hereditary/acquired angioedema (HAE)

— If low or recurrent angioedema without wheals: C1-INH level and function, C1q (C1q low in acquired, normal in hereditary)

— ANA if features of connective tissue disease

— Stool ova and parasites only with travel/exposure/eosinophilia

— H. pylori testing if dyspepsia — eradication may improve CSU in selected patients

— Tryptase — elevated baseline (>11.4 ng/mL, ideally >20) suggests mastocytosis or hereditary alpha-tryptasemia

— Food-specific IgE panels, environmental allergen panels, total IgE — low yield in CSU, drive false positives and unnecessary elimination diets

— Extensive autoimmune panels without features

— Skin prick testing for foods in absence of reproducible reaction

— Cold stimulation test: ice cube on forearm × 5 min, observe 10 min for wheal

— FricTest: calibrated dermographometer for symptomatic dermographism

— Pressure test: 7 kg weight on shoulder × 15 min, read at 6 h, for delayed pressure urticaria

— Exercise/passive warming: cholinergic vs exercise-induced anaphylaxis

Guideline-directed minimum workup for CSU (AAAAI/ACAAI 2014, EAACI/GA²LEN 2022)

Tests to add only when history-directed

Tests to NOT routinely order

CIndU confirmatory testing

Step 3 management: Reassure patients that "no cause found" in CSU is the expected result — finding a specific allergen is the exception. Frame the workup around ruling out mimics (thyroid, vasculitis, HAE, mastocytosis) rather than identifying triggers.

Board pearl: Recurrent angioedema + low C4 + low C1-INH antigenic level = HAE type I (85%); low C4 + normal C1-INH level but low function = HAE type II.

Diagnostic Workup — Advanced and Confirmatory Studies

— Intradermal injection of patient's own serum; wheal ≥1.5 mm larger than control suggests autoreactive CSU

— Not required for diagnosis; does not change initial therapy; mainly research/specialist use

— Identify autoimmune type IIb CSU (~10%); these patients tend to respond less well to omalizumab and may benefit from cyclosporine or future BTK inhibitors

— Available at specialty centers only

— Individual lesions lasting >24 hours

— Painful or burning rather than pruritic

— Residual purpura, hyperpigmentation, or scarring

— Systemic symptoms (fever, arthralgia, weight loss)

— Findings:

— Urticarial vasculitis: leukocytoclastic vasculitis on H&E, +/- immune complexes on DIF

— Mastocytosis: increased dermal mast cells (CD117, tryptase stain); KIT D816V mutation

— Schnitzler syndrome: neutrophilic urticarial dermatosis + monoclonal IgM gammopathy

— Generally not indicated for CSU

— Abdominal CT during attack of unexplained recurrent abdominal pain with angioedema → bowel wall edema supports HAE

— Total IgE may guide omalizumab response (higher baseline IgE → better response), but not required to start therapy

— UAS7 (urticaria activity score, 7-day)

— UCT (urticaria control test)

— DLQI (dermatology life quality index)

— AECT (angioedema control test)

— CSU: wheals <24 h, pruritic, no scarring, normal complement, normal C1-INH

— Urticarial vasculitis: wheals >24 h, burning, purpura/hyperpigmentation, low complement

— HAE: angioedema only, no wheals, no pruritus, low C4, abdominal attacks

— Mastocytosis: Darier sign, elevated tryptase, flushing, syncope

Autologous serum skin test (ASST)

Basophil activation test (BAT) and anti-FcεRI ELISA

Skin biopsy — indications

Imaging

Serum IgE level

Documentation tools to track over time

Key distinction:

Board pearl: A patient with chronic urticaria, intermittent fever, bone pain, and monoclonal IgM on SPEP → Schnitzler syndrome; treat with IL-1 inhibitor (anakinra, canakinumab), not antihistamines.

Stepwise Management Algorithm — EAACI/AAAAI Logic

— Complete symptom control (UAS7 = 0, UCT = 16) with the fewest side effects

— Not "fewer flares" — full suppression is the modern target

— Cetirizine 10 mg, levocetirizine 5 mg, fexofenadine 180 mg, loratadine 10 mg, desloratadine 5 mg, bilastine 20 mg daily

— Reassess in 2–4 weeks

— Increase up to 4× standard dose (off-label but guideline-endorsed and safe)

— e.g., cetirizine 10 mg up to 4 tabs daily

— Avoid mixing multiple sedating antihistamines; do not add first-generation as scheduled therapy

— Reassess in 2–4 weeks

— Anti-IgE monoclonal antibody, 300 mg SC every 4 weeks

— FDA-approved for CSU in patients ≥12 unresponsive to H1 antihistamines

— Response often within 1–2 doses; if no response after 6 months at 300 mg, consider step 4

— 2.5–5 mg/kg/day; specialist-managed

— Monitor BP, renal function, magnesium, lipids

— Reserved for omalizumab-refractory disease

— Short-course oral corticosteroids (e.g., prednisone 40 mg × 3–7 days) for severe flares only — not for chronic maintenance

— Avoid NSAIDs, opiates, alcohol, tight clothing during flares

— Treat identified comorbidities (hypothyroidism, H. pylori)

— Stop ACEi if any angioedema history

Goal of therapy

Step 1 — Standard-dose second-generation H1 antihistamine

Step 2 — Updose second-generation H1 antihistamine

Step 3 — Add omalizumab

Step 4 — Cyclosporine

Adjuncts and avoidance

Step 3 management: Primary care can comfortably manage steps 1 and 2. Refer to allergy/immunology when updosed antihistamines fail at 2–4 weeks, when angioedema is prominent, or when systemic steroids are being repeatedly required.

Board pearl: Chronic daily prednisone is never the right Step 3 answer for CSU maintenance — the correct next step after failed updosed H1 antihistamines is omalizumab, not steroids.

Pharmacotherapy — First-Line and Second-Line Drug Detail

— Cetirizine 10 mg daily, updose to 40 mg/day; mild sedation in ~10%

— Levocetirizine 5 mg, updose to 20 mg/day; active enantiomer of cetirizine

— Fexofenadine 180 mg daily, updose to 720 mg/day; least sedating, preferred for drivers, pilots, operators

— Loratadine/desloratadine 10/5 mg, updose to 40/20 mg/day

— Bilastine 20 mg daily (US-approved 2024); minimal hepatic metabolism, no QT effect

— Take on a schedule, not PRN — wheal suppression requires steady drug levels

— First-generation antihistamines (diphenhydramine, hydroxyzine) — sedation, anticholinergic burden, falls in elderly, dementia association

— May use hydroxyzine 25 mg qHS short-term for pruritus-driven insomnia, but not daytime

— Famotidine 20–40 mg BID — modest add-on benefit; consider before stepping up to biologic

— Montelukast 10 mg daily — may help NSAID-exacerbated or aspirin-sensitive urticaria

— Boxed warning: neuropsychiatric effects (mood changes, suicidality) — counsel and document

— 300 mg SC q4 weeks; observation period 2 h for first 3 doses (anaphylaxis risk ~0.1%)

— Prescribe epinephrine auto-injector alongside

— No baseline IgE or weight dosing needed for CSU (unlike asthma)

— Pregnancy category formerly B; registry data reassuring

— 2.5–5 mg/kg/day divided BID

— Monitor BP, BUN/Cr, K, Mg, uric acid, lipids q2 weeks initially

— Avoid in uncontrolled HTN, renal impairment, malignancy history

— Dupilumab (anti-IL-4Rα) — FDA approved for CSU in 2025

— Remibrutinib (BTK inhibitor) — pending approval

Second-generation H1 antihistamines (first line)

Avoid as chronic therapy

H2 antihistamines

Leukotriene receptor antagonists

Omalizumab (second line / step 3)

Cyclosporine (third line)

Emerging

Board pearl: Updosing a non-sedating antihistamine to 4× is safer and more effective than adding a sedating first-generation antihistamine at bedtime — this is a favorite Step 3 trap.

Special Situations — Angioedema, Acute Flares, and Biologic Initiation

— Assess airway, breathing, circulation

— If any laryngeal/tongue swelling, stridor, hypotension, wheeze → treat as anaphylaxis:

— IM epinephrine 0.3–0.5 mg (0.01 mg/kg peds, max 0.5 mg) lateral thigh, repeat q5–15 min

— IV fluids, supplemental O2, position supine with legs elevated

— H1 (cetirizine IV or diphenhydramine 25–50 mg IV) + H2 (famotidine 20 mg IV) + methylprednisolone 60–125 mg IV (adjunct, not first-line)

— Observe 4–6 h (biphasic risk); discharge with 2 epinephrine auto-injectors, oral antihistamine 5–7 days, allergy referral

— Responds to antihistamines and steroids; epinephrine for airway involvement

— Does not respond to epinephrine, antihistamines, or steroids

— HAE acute attack: IV C1-INH concentrate (Berinert, Cinryze), icatibant (bradykinin B2 antagonist), or ecallantide (kallikrein inhibitor)

— HAE prophylaxis: lanadelumab SC q2 weeks, berotralstat oral daily, IV C1-INH q3–4 days

— ACEi angioedema: stop ACEi permanently; FFP or icatibant for severe attacks; ARBs generally tolerated but use cautiously

— Confirm step 1+2 failure documented (UCT <12 on max-dose antihistamines × 2–4 weeks)

— Verify insurance prior authorization

— Administer in office with 2-hour post-injection observation × first 3 doses; then 30 min thereafter

— Reassess UCT/UAS7 at each visit; if controlled × 6 months, consider extending interval or tapering

Acute severe urticaria flare in the office or ED

Histaminergic angioedema (CSU-associated)

Bradykinin-mediated angioedema (HAE, ACEi-induced)

Omalizumab initiation logistics

CCS pearl: In a CCS case of angioedema after starting lisinopril for hypertension: order — discontinue ACEi, secure airway (consider early intubation if tongue/laryngeal involvement), IV access, observation in monitored bed; on discharge, document ACEi allergy, switch to ARB or CCB, counsel patient and family, update problem list.

Special Populations — Elderly and Renal/Hepatic Impairment

— Avoid first-generation antihistamines (diphenhydramine, hydroxyzine, chlorpheniramine) — on Beers Criteria for inappropriate use in older adults due to anticholinergic burden, sedation, falls, delirium, urinary retention, dementia association

— Preferred second-generation agents:

— Loratadine, desloratadine, fexofenadine — minimal CNS penetration

— Cetirizine/levocetirizine — slight sedation; use lower starting dose

— Polypharmacy review: QT-prolonging drugs (uncommon with modern antihistamines but check), CYP3A4 interactions (cyclosporine), anticholinergic stacking

— Cetirizine: CrCl 30–50 → 5 mg daily; CrCl <30 → 5 mg every other day; avoid in dialysis if alternatives exist

— Levocetirizine: CrCl 50–80 → 2.5 mg daily; 30–50 → 2.5 mg every other day; 10–30 → 2.5 mg twice weekly

— Fexofenadine: CrCl <80 → 60 mg daily

— Desloratadine: 5 mg every other day in renal impairment

— Loratadine: 10 mg every other day if CrCl <30

— Omalizumab: no renal adjustment needed

— Cyclosporine: avoid if possible; nephrotoxic

— Loratadine, desloratadine: reduce to every-other-day dosing in severe hepatic impairment

— Fexofenadine: minimal hepatic metabolism — preferred in cirrhosis

— Bilastine: not metabolized hepatically — also preferred

— Cyclosporine: hepatic metabolism; monitor levels and LFTs

— Document baseline cognition before initiating antihistamines that can cause confusion

— Use the smallest effective dose; updose cautiously, one step at a time, with reassessment in 2 weeks

Elderly considerations

Renal impairment dose adjustments

Hepatic impairment

Frailty and cognitive screening

Step 3 management: When an 80-year-old presents with new chronic urticaria, screen specifically for drug-induced causes (new ACEi, ARB, NSAIDs, PPI, statin) and for paraneoplastic angioedema or urticarial vasculitis before committing to indefinite antihistamines.

Board pearl: New-onset urticaria in an elderly patient with weight loss and elevated ESR → workup for occult malignancy, vasculitis, or Schnitzler syndrome — not just CSU.

Special Populations — Pregnancy, Lactation, and Pediatrics

— CSU often worsens in the third trimester; ~30% improve, ~30% worsen, ~40% unchanged

— First-line: loratadine or cetirizine — most safety data, no increased risk of major malformations

— Levocetirizine and desloratadine — likely safe; less data

— Avoid hydroxyzine in the first trimester (FDA warning); avoid in late pregnancy (neonatal sedation)

— Diphenhydramine — acceptable short-term; avoid near term (uterine contractions reported in high doses)

— Short-course prednisone acceptable for severe flares; avoid in first trimester if possible (cleft palate risk debated, small absolute increase)

— Omalizumab — pregnancy registry (EXPECT) shows no increased malformation rate; continue if clinically necessary

— Cyclosporine — used safely in transplant pregnancies; specialist decision

— Avoid montelukast, leukotriene modifiers unless clear benefit

— Loratadine and cetirizine preferred — minimal milk transfer, no infant sedation

— Avoid first-generation antihistamines (sedation in infant, possible decreased milk supply)

— CSU in children: prevalence ~0.1–0.3%; most resolve within 5 years

— Second-generation H1 antihistamines are first line; dosing:

— Cetirizine: 6 mo–2 y, 2.5 mg daily; 2–6 y, 2.5–5 mg; ≥6 y, 5–10 mg

— Loratadine: 2–5 y, 5 mg daily; ≥6 y, 10 mg

— Fexofenadine: ≥2 y per label

— Updose to 4× as in adults if needed (specialist guidance for very young children)

— Omalizumab approved ≥12 years for CSU

— Watch for growth, school performance, sleep in chronic disease

— Always assess for chronic infection (strep, dental, sinus), inducible triggers (cold most common), and family history of HAE

Pregnancy

Lactation

Pediatrics

Key distinction: In a pediatric patient with recurrent angioedema without urticaria and a positive family history, check C4 and C1-INH — HAE often manifests in adolescence and is frequently missed for years.

Board pearl: Pregnant patient with worsening hives at 32 weeks — loratadine 10 mg daily, updose to 40 mg if needed is the correct answer; not diphenhydramine, not prednisone first.

Complications and Adverse Outcomes

— Sleep disruption and fatigue — wheals and pruritus peak at night; cumulative sleep debt affects mood, work, driving safety

— Mood disorders — depression and anxiety prevalence 2–3× general population in CSU

— Suicidality — increased risk; screen at every visit (PHQ-9)

— Work and school absenteeism — average 1 day/month lost in moderate-severe CSU

— Skin changes — excoriations, secondary bacterial infection from scratching, post-inflammatory hyperpigmentation

— Airway compromise — laryngeal angioedema, rare but life-threatening in CSU-associated angioedema; more frequent in HAE/ACEi

— First-generation antihistamines: sedation, anticholinergic effects, paradoxical excitation in children, cognitive impairment, falls and fractures in elderly

— Second-generation antihistamines at high doses: mild sedation (cetirizine, levocetirizine), dry mouth; cetirizine withdrawal pruritus — distinctive flare on abrupt discontinuation after long-term use

— Omalizumab: injection-site reaction, headache, arthralgia; anaphylaxis ~0.1–0.2% (usually within 2 h); rare malignancy signal not confirmed in CSU trials

— Cyclosporine: hypertension, nephrotoxicity, hyperkalemia, hypomagnesemia, hyperlipidemia, gingival hyperplasia, hirsutism, infection, malignancy (esp. skin) with long-term use

— Systemic corticosteroids: hyperglycemia, osteoporosis, mood, weight gain, adrenal suppression, infection — why chronic use is inappropriate

— Montelukast: neuropsychiatric (boxed warning) — depression, sleep disturbance, suicidal ideation

— Recurrent ED visits and unnecessary epinephrine use without proper outpatient escalation

— Diagnostic odyssey with repeated allergy panels, elimination diets, expense, frustration

Disease-related complications

Treatment-related adverse effects

Healthcare utilization

Step 3 management: Recognize chronic steroid dependence as a complication and a quality-of-care red flag. A patient receiving >2 prednisone bursts/year for urticaria belongs on omalizumab — refer.

Board pearl: A patient on long-term cetirizine who stops abruptly and develops severe generalized pruritus without wheals → cetirizine discontinuation pruritus; restart cetirizine and taper slowly over weeks.

When to Escalate — Referral, ED, and Inpatient Triage

— UCT <12 or UAS7 >6 despite 4× standard-dose second-generation H1 antihistamine for ≥4 weeks

— Recurrent angioedema regardless of urticaria control

— Suspicion of HAE (recurrent angioedema without wheals, abdominal attacks, family history, low C4)

— Need for omalizumab, cyclosporine, or other biologic

— Diagnostic uncertainty (urticarial vasculitis, mastocytosis, Schnitzler, autoinflammatory)

— Patients dependent on systemic steroids

— Wheals lasting >24 h with purpura or hyperpigmentation → biopsy for urticarial vasculitis

— Suspected mastocytosis (Darier sign, telangiectatic macules)

— Urticarial vasculitis confirmed; SLE features; autoinflammatory syndromes (Schnitzler, CAPS)

— Stridor, voice change, dyspnea, tongue/throat swelling

— Hypotension, syncope, persistent vomiting → anaphylaxis

— Severe angioedema not responding to home antihistamines

— Airway angioedema requiring monitoring or intubation

— Anaphylaxis with biphasic risk features (delayed presentation, prolonged response, requirement for repeat epinephrine)

— HAE attack requiring IV C1-INH or icatibant in setting unable to manage as outpatient

— Cyclosporine-induced AKI, hypertensive emergency, or infection

— Intubated angioedema, refractory anaphylaxis, vasopressor requirement

— Confirm prescription for scheduled second-generation H1 antihistamine

— Two epinephrine auto-injectors if any systemic features

— Document allergy (ACEi, NSAID) in EHR allergy field — not just the note

— Allergy/immunology follow-up within 2 weeks

— Patient education: action plan, when to use epinephrine, when to return

Refer to allergy/immunology when:

Refer to dermatology when:

Refer to rheumatology when:

Emergency department / 911 criteria

Inpatient admission criteria

ICU criteria

Transition-of-care checklist on ED discharge for acute flare

CCS pearl: In a CCS case, after stabilizing angioedema and observation, the right discharge orders include — discontinue ACEi, prescribe ARB or alternative antihypertensive, epinephrine auto-injector ×2, second-generation antihistamine, allergy consult outpatient, patient education, and update problem list with "angioedema, ACEi-induced."

Key Differentials — Other Urticarial and Angioedema Syndromes

— Usually infection (viral URI in children), drug (beta-lactams, NSAIDs), food, or insect sting

— Self-limited; treat symptomatically

— Symptomatic dermographism: linear wheals after stroking

— Cold urticaria: wheal on rewarming after cold exposure; risk of anaphylaxis from cold water immersion (counsel against swimming alone)

— Cholinergic urticaria: small punctate wheals with heat, exercise, emotion; mostly young adults

— Delayed pressure urticaria: deep painful swelling 4–6 h after sustained pressure (belts, sitting)

— Solar urticaria: wheals on UV-exposed skin within minutes

— Aquagenic urticaria: wheals from water contact regardless of temperature

— Vibratory urticaria/angioedema: autosomal dominant in some kindreds (ADGRE2 mutation)

— Exercise-induced anaphylaxis (often food-dependent, e.g., wheat + exercise): wheals, hypotension, requires food avoidance pre-exercise and epinephrine

— Wheals >24 h, painful/burning, purpura, hyperpigmentation

— Hypocomplementemic form (low C3/C4) associated with SLE, anti-C1q antibodies

— Biopsy: leukocytoclastic vasculitis

— Treat: NSAIDs (paradoxically helpful), colchicine, dapsone, hydroxychloroquine, systemic immunosuppression

— Chronic urticaria + monoclonal IgM (rarely IgG) + ≥2: fever, bone pain, arthralgia, lymphadenopathy, hepatosplenomegaly, elevated CRP/ESR, leukocytosis

— IL-1 driven → anakinra or canakinumab

— Cutaneous (urticaria pigmentosa, Darier sign) or systemic

— Elevated tryptase >20 baseline; KIT D816V mutation

— Avoid mast-cell triggers; epinephrine auto-injector; specialist care

Acute urticaria (<6 weeks)

Chronic inducible urticaria (CIndU) — reproducible trigger

Urticarial vasculitis

Schnitzler syndrome

Mastocytosis / mast cell activation syndrome

Key distinction: Wheal duration is the single most useful bedside differential — <24 h migratory wheals = CSU/CIndU; >24 h fixed wheals with residual skin change = urticarial vasculitis or autoinflammatory syndrome.

Board pearl: Cold urticaria patient who jumps into a cold pool → systemic mast cell degranulation → cardiovascular collapse. Counsel against full-body cold immersion; prescribe epinephrine auto-injector.

Key Differentials — Non-Urticarial Mimics

— Hereditary angioedema (HAE): autosomal dominant; low C4, low C1-INH (type I) or dysfunctional C1-INH (type II); HAE with normal C1-INH (factor XII or others); recurrent angioedema, abdominal pain attacks, no urticaria

— Acquired angioedema (AAE): associated with lymphoproliferative disease or autoantibodies; low C1q (distinguishes from HAE)

— ACEi/ARB-induced angioedema: more common in Black patients; can occur years after starting; stop drug permanently

— Pruritic, but vesicles, scaling, lichenification; distribution matches contactant

— Patch testing rather than IgE testing

— Elderly patient with persistent urticarial plaques that don't resolve; eventually tense bullae

— DIF: linear IgG and C3 at basement membrane

— Targetoid lesions with dusky center, fixed for days; not migratory; mucosal involvement

— Third-trimester pruritic urticarial papules in striae, sparing umbilicus

— Periumbilical urticarial plaques progressing to vesicles; DIF positive

— Pure dermatographism: linear wheals only at sites of friction; no spontaneous wheals

— Unilateral, warm, tender, systemic symptoms; not migratory; does not resolve within hours

— Round, dusky, recurrent at the same site with each exposure; resolves with hyperpigmentation

— Non-pitting puffiness, especially periorbital; not paroxysmal; abnormal TSH

— Facial swelling, plethora, dilated chest collaterals; not paroxysmal; consider malignancy

Bradykinin-mediated angioedema

Contact dermatitis / allergic dermatitis

Bullous pemphigoid (urticarial prebullous phase)

Erythema multiforme

Polymorphic eruption of pregnancy (PEP/PUPPP)

Pemphigoid gestationis

Dermatographism vs CSU

Cellulitis / erysipelas

Fixed drug eruption

Hypothyroidism / myxedema

Superior vena cava syndrome

Step 3 management: A patient on an ACEi for 3 years who develops first episode of lip swelling — the answer is stop the ACEi, even if the patient has tolerated it for years; latency does not exclude causation. Switch to a non-ACEi/ARB regimen (CCB, thiazide, ARB with caution) and document allergy.

Board pearl: Recurrent angioedema + normal C4 essentially rules out classic HAE type I/II; consider ACEi, idiopathic histaminergic angioedema, HAE with normal C1-INH, or AAE — and recheck C4 during an attack, when it should be lowest.

Long-Term Plan, Maintenance, and Secondary Prevention

— Goal: UCT 16 / UAS7 0 with monotherapy at the lowest effective dose

— Reassess every 3–6 months once controlled; many patients can step down

— CSU is self-limited in most: median 2–5 years; reassess need for therapy annually

— After 3–6 months of complete control:

— Reduce antihistamine dose by half; reassess in 4 weeks

— If on omalizumab + antihistamine, lengthen omalizumab interval to q6 weeks, then q8 weeks

— Continue antihistamine scheduled, not PRN, even during stable periods

— If flare on stepdown, return to previous effective dose

— NSAIDs: avoid in patients with NSAID-exacerbated urticaria; acetaminophen and COX-2 selective often tolerated

— Opioids: minimize; cause non-IgE mast cell degranulation

— Alcohol, spicy foods, heat: variable; individualized counsel

— Stress: associated with flares; integrate stress-management resources

— ACEi: absolute contraindication if any angioedema history

— Treat autoimmune thyroid disease even if subclinical when associated with CSU

— H. pylori eradication if positive — may improve urticaria in subset

— Screen and manage anxiety/depression (PHQ-9, GAD-7)

— Optimize vitamin D — low levels associated with CSU; supplementation if deficient

— Routine vaccines are not contraindicated; vaccinate annually for influenza

— COVID-19 vaccination safe in CSU; transient flare possible

— Written action plan: daily medication, flare medication, when to use epinephrine, when to call/visit

— Epinephrine auto-injector ×2 if any history of angioedema or anaphylaxis; renew annually

— Medical alert bracelet for ACEi allergy or HAE

Maintenance philosophy

Stepdown approach

Trigger and exacerbator avoidance

Comorbidity management

Vaccination

Patient self-management toolkit

Step 3 management: At each annual physical, review whether antihistamine therapy is still needed — many adult CSU patients experience spontaneous remission and continue medications unnecessarily for years.

Board pearl: A patient controlled on omalizumab × 12 months — do not stop abruptly; extend the dosing interval (q6, then q8 weeks) while monitoring UCT; ~one-third remain symptom-free off therapy.

Follow-Up, Monitoring, and Counseling Cadence

— 2–4 weeks after starting or updosing antihistamines: assess UCT, side effects, adherence

— Every 3 months during titration or biologic initiation

— Every 6 months once stable; consider stepdown

— Annually for chronic remission monitoring

— UAS7 (last 7 days; >6 = uncontrolled)

— UCT (≥12 = controlled, 16 = complete control)

— AAS if angioedema-predominant

— DLQI for quality-of-life impact

— PHQ-9 / GAD-7 at least annually

— Antihistamine monotherapy: no routine labs needed; recheck TSH annually if autoimmune thyroid present

— Omalizumab: no routine labs needed; track UCT, injection-site reactions

— Cyclosporine: BP, BUN/Cr, K, Mg, uric acid, LFTs, lipids q2 weeks × 1 month, then monthly; trough levels if compliance concern

— Systemic steroid use (any): glucose, BP, bone density if prolonged, ophthalmologic check

— Take antihistamines scheduled, not PRN — steady-state suppression

— Skin lesions from scratching are not the urticaria itself; keep nails short, use cool compresses, fragrance-free moisturizers

— Avoid hot showers immediately before bed (can trigger pruritus)

— Cetirizine withdrawal can cause rebound pruritus — taper, don't stop abruptly

— CSU is not contagious, not "allergic," not caused by diet in the vast majority

— Elimination diets are usually unhelpful and may cause nutritional harm

— Patients on first-generation antihistamines or high-dose cetirizine should avoid operating heavy machinery until tolerance assessed

— Pilots, commercial drivers — prefer fexofenadine or bilastine (least CNS effect)

— Pre-conception visit: choose loratadine or cetirizine; review omalizumab data; avoid montelukast if possible

Visit cadence (primary care)

Tools to use at every visit

Lab monitoring

Patient counseling pearls

Driving and occupational counseling

Pregnancy planning

Step 3 management: Use the UCT score in the chart at every visit — payers increasingly require documented severity scores for omalizumab prior authorization, and Step 3 vignettes often hinge on the patient's UCT/UAS7 trend, not just symptom narrative.

Board pearl: A "well-controlled" CSU patient still on prednisone 10 mg daily is not well-controlled — the appropriate next step is omalizumab and steroid taper, not continued steroids.

Ethical, Legal, and Patient Safety Considerations

— Omalizumab anaphylaxis risk (~0.1–0.2%) must be disclosed; document discussion of black-box warning

— Provide and document epinephrine auto-injector prescription and training

— Discuss off-label updosing of antihistamines transparently — patients should understand that 4× the package dose is guideline-supported but exceeds the FDA label

— Cyclosporine, montelukast, dapsone, dupilumab (in some markets) for CSU are off-label

— Discuss financial cost of omalizumab (~$1,500–3,000/month list price) and patient assistance programs; biosimilars now available

— Insurance prior authorization requires documented step-therapy failure — keep visit notes specific

— On ED discharge after angioedema: update EHR allergy field, not just the note — ACEi-induced angioedema is a leading sentinel event when a downstream prescriber misses the history

— Medication reconciliation at every transition; verify ACEi/ARB status

— Communicate omalizumab schedule and last dose to covering clinicians

— Severe adverse drug reactions (Stevens-Johnson, DRESS) → report to FDA MedWatch

— Suspected anaphylaxis deaths → notify medical examiner

— Cyclosporine-related malignancies → cancer registry where applicable

— Adolescents on omalizumab — engage in shared decision-making; assess school accommodations for daily symptoms

— Confidentiality around mental health (depression screening) per state minor consent laws

— Severe CSU may qualify for ADA accommodations (flexible scheduling, dress code modifications for pressure urticaria)

— Cold urticaria patients may need workplace temperature adjustments

— In dying patients with comfort-focused care, simplify antihistamines and discontinue immunomodulators

Informed consent for biologics

Off-label and cost transparency

Transitions of care

Mandatory reporting and safety

Pediatric and adolescent autonomy

Disability and occupational law

End-of-life considerations

Step 3 management: A patient with ACEi-induced angioedema is discharged on the same ACEi because the inpatient team did not update the home med list — this is a classic patient safety failure. At every Step 3 transition-of-care scenario, the correct action is to explicitly discontinue the offending agent, document the allergy in the structured allergy field, and provide written and verbal counseling to the patient and outpatient team.

Board pearl: Failure to prescribe epinephrine auto-injectors after a clearly anaphylactic episode is below the standard of care and a frequently tested patient safety endpoint.

High-Yield Associations and Rapid-Fire Facts

— Chronic = ≥6 weeks; wheals <24 h; angioedema may last 48–72 h

— Lifetime urticaria ~20%; CSU ~1%; F:M = 2:1; peak 20–40

— Mast cell-driven, histamine + LTC4/D4/E4 + PAF; autoimmune type IIb in ~10% (anti-FcεRI)

— CBC, CRP/ESR, TSH — that's it routinely; add C4 only if angioedema without wheals; biopsy only if atypical

— Second-generation H1 antihistamine, scheduled, updosed to 4× if needed

— Omalizumab 300 mg SC q4 weeks

— Cyclosporine 2.5–5 mg/kg/day

— Systemic corticosteroids, first-generation antihistamines, opioids, NSAIDs (if exacerbating)

— Autoimmune thyroid disease (~25%) — anti-TPO most common

— Vitamin D deficiency

— H. pylori (controversial, variable response to eradication)

— Celiac disease (small association)

— SLE, RA, type 1 DM (autoimmune cluster)

— Loratadine or cetirizine preferred

— Cetirizine from 6 months; omalizumab from 12 years

— Recurrent angioedema, abdominal pain, family history, no wheals, low C4

— Type I: low C1-INH antigen; Type II: normal antigen, low function

— Acquired: low C1q (vs normal in HAE)

— Treatment: C1-INH concentrate, icatibant, ecallantide; prophylaxis with lanadelumab or berotralstat

— Higher risk in Black patients; can occur years after initiation

— Stop ACEi permanently; ARBs cautiously acceptable

— Risk of cardiovascular collapse with whole-body cold exposure

— Counsel against unsupervised swimming; epinephrine auto-injector

— Darier sign, elevated tryptase, KIT D816V; epinephrine auto-injector mandatory

— Chronic urticaria + monoclonal IgM + fever/bone pain; IL-1 blockade

— Wheals >24 h, burning, purpura; low complement (hypocomplementemic form); leukocytoclastic vasculitis on biopsy

Definitions

Epidemiology

Pathophysiology

Workup essentials

First-line treatment

Second-line

Third-line

Avoid chronically

Associations

Pregnancy and lactation

Pediatrics

HAE clues

ACEi angioedema

Cold urticaria

Mastocytosis

Schnitzler

Urticarial vasculitis

Board pearl: Three diagnoses you must always exclude before labeling a patient "chronic spontaneous urticaria": HAE, urticarial vasculitis, and mastocytosis — they each have different therapies and prognoses.

Board Question Stem Patterns

— Next step: Updose cetirizine to 40 mg daily (4× standard) — not add diphenhydramine, not start prednisone, not order food allergy panel.

— Diagnosis: ACEi-induced bradykinin angioedema.

— Management: stop lisinopril permanently, secure airway, consider icatibant; discharge on non-ACEi antihypertensive (CCB or thiazide); document allergy.

— Diagnosis: Urticarial vasculitis (hypocomplementemic).

— Next step: skin biopsy showing leukocytoclastic vasculitis; evaluate for SLE.

— Best plan: continue cetirizine or switch to loratadine; avoid first-trimester systemic steroids; avoid hydroxyzine.

— Next step: omalizumab 300 mg SC q4 weeks (approved ≥12 y), with epinephrine auto-injector prescription.

— Order: C4, C1-INH level and function.

— Diagnosis: HAE; treatment with C1-INH concentrate or icatibant acutely; long-term prophylaxis with lanadelumab.

— Diagnosis: Schnitzler syndrome.

— Treatment: anakinra or canakinumab.

— Best next step: start omalizumab and taper prednisone — chronic steroids inappropriate.

— Diagnosis: cold urticaria with systemic anaphylaxis.

— Plan: IM epinephrine, observation, prescribe auto-injector ×2, counsel against cold-water immersion.

— Workup: malignancy screen, SPEP, biopsy — not just antihistamines.

Stem 1: A 34-year-old woman has daily hives for 8 weeks; TSH, CBC, CRP normal; cetirizine 10 mg daily provides partial relief.

Stem 2: A 58-year-old man on lisinopril × 3 years presents with isolated lip and tongue swelling, no urticaria, no itch.

Stem 3: A patient with daily wheals lasting >24 h, burning sensation, residual hyperpigmentation, low C4, arthralgia.

Stem 4: A 28-year-old woman with CSU controlled on cetirizine 40 mg daily becomes pregnant.

Stem 5: A 16-year-old with CSU uncontrolled despite cetirizine 20 mg, fexofenadine 360 mg, and famotidine.

Stem 6: A 40-year-old with recurrent angioedema, abdominal pain attacks, family history of similar episodes, no urticaria.

Stem 7: Patient with chronic urticaria, intermittent fever, bone pain, monoclonal IgM gammopathy.

Stem 8: A patient on prednisone 10 mg daily × 6 months for CSU returns with weight gain, hyperglycemia, controlled hives.

Stem 9: A child plunges into a cold lake and develops syncope and generalized hives.

Stem 10: An 80-year-old with new-onset urticaria, fatigue, 10-lb weight loss, ESR 80.

Board pearl: When the stem includes "wheals last >24 hours, burn rather than itch, leave bruising" — the answer is biopsy for urticarial vasculitis, not increase antihistamine.

One-Line Recap

Chronic urticaria/angioedema is a clinical diagnosis treated stepwise with scheduled second-generation H1 antihistamines, updosed up to 4× before adding omalizumab, while carefully excluding bradykinin-mediated angioedema (HAE, ACEi), urticarial vasculitis, and mastocytosis — and never relying on chronic systemic steroids.

Diagnose clinically: hives ≥6 weeks, individual wheals <24 h, no specific allergy workup needed beyond CBC, CRP/ESR, and TSH; pursue C4/C1-INH only when angioedema occurs without urticaria, and biopsy only when lesions are atypical (>24 h, painful, purpuric).

Treat in clear steps: scheduled second-generation H1 antihistamine → updose to 4× → omalizumab 300 mg SC q4 weeks → cyclosporine for refractory disease; use short prednisone bursts only for severe flares, never as maintenance.

Recognize mimics that change everything: ACEi-induced and hereditary angioedema do not respond to antihistamines, steroids, or epinephrine and require bradykinin-targeted therapy; urticarial vasculitis demands biopsy and immunomodulation; mastocytosis and Schnitzler syndrome have distinct biomarkers (tryptase, monoclonal IgM) and treatments.

Manage longitudinally and safely: track UCT/UAS7 at every visit, screen for depression and sleep impact, prescribe epinephrine auto-injectors when angioedema or anaphylaxis history exists, update structured allergy fields after any ACEi reaction, and reassess annually for spontaneous remission so patients are not left on indefinite therapy.

Step 3 management: The single most testable Step 3 decision point is recognizing when to stop escalating antihistamines and refer for omalizumab — not when to add another sedating antihistamine, and never to commit a patient to chronic systemic corticosteroids.